Sign in
Taking people in United StatesNo phase

Tests a TheraBionic P1 device in adults with advanced liver cancer

Tests a device in adults with advanced liver cancer after other treatments.

Key facts

Who runs it
Barbara Ann Karmanos Cancer Institute
Where
Ann Arbor, Bay City, Detroit, Flint, Houston, Lansing, Lapeer, and Mount Pleasant, United StatesSee the 8 sites
Trial code
Registry title
TheraBionic P1 Device in Subjects With Advanced Hepatocellular Carcinoma
Status
Recruiting
People taking part
198 people, planned
Started
20 Oct 2025
Expected to end
31 Aug 2028
Type of study
Interventional
Treatments tested
  • TheraBionic P1
Record updated
12 November 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with advanced liver cancer (hepatocellular carcinoma) who have no standard treatment options left and can use the TheraBionic P1 device.

Age
22 years or older
Sex
All sexes can join.
Disease stage
Advanced hepatocellular carcinoma: a liver tumor that cannot have local therapy because of how far it has spread, or that came back after local therapy. The disease must be measurable.
Earlier treatment
Have failed at least two lines of therapy, or can no longer have any standard therapy, or cannot tolerate at least two lines of therapy.

Main reasons for not taking part

  • Known active second cancer, unless the investigator thinks it will not interfere with the trial
  • Taking any other investigational drugs
  • Active inflammation, ulcers or other problems in the mouth that could interfere with the device
  • Taking calcium channel blockers or similar drugs, unless stopped before treatment
  • Breastfeeding, unless breastfeeding is stopped

The registry criteria, word for word

Show all 13 criteriaShow less

Who can take part

  • Patients with advanced hepatocellular carcinoma (HCC) (defined as a liver tumor not eligible for local therapies given the extent of disease or a livor tumor that recurred after local therapy)
  • Patients who have failed at least two lines of therapy* or who are no longer eligible for any line of standard therapy or who are intolerant to at least two lines of therapy
  • Patients with evaluable disease
  • Patients must be ≥ 22 years old and must be able to understand and sign an informed consent
  • Female patients of childbearing potential and their partners and male patients must agree to use adequate contraception during the period of study treatment
  • Patients with a life expectancy of at least 3 months

Who cannot take part

  • Patients taking any other investigational drugs
  • Patients with known active secondary malignancy, unless, in the opinion of the investigator, it is unlikely to interfere with the safety and efficacy of the endpoints
  • Patients with a known severe (e.g., anaphylactic) allergy to nickel
  • Patients receiving calcium channel blockers and any agent blocking L-type of T-type Voltage Gated Calcium Channels, e.g., amlodipine, nifedipine, ethosuximide, ascorbic acid (vitamin C), etc. unless their medical treatment is discontinued to prior to treatment on study. Patients must agree to abstain from using calcium channel blockers and any agent blocking L-type or T-type voltage gated calcium channels for the duration of treatment on study
  • Patients with active oral mucosal inflammation, ulceration, or other pathology that could interfere with the use of the device
  • Patients who are breastfeeding. If a breastfeeding participant would like to be part of this study, breastfeeding must be discontinued
  • Patients that do not agree to be followed according to the study protocol or have cognitive or physical inability to use the device for the prescribed period and frequency (three 60-minute treatments in the morning, middle of the day, and evening)

Where in United States

  • University of MichiganAnn Arbor, United StatesContact: Vaibhav Sahai, MDTaking people
  • Karmanos Cancer Institute at McLaren Bay RegionBay City, United StatesContact: Anthony F Shields, M.D.Taking people
  • Karmanos Cancer InstituteDetroit, United StatesContact: Anthonly F Shields, M.D.Taking people
  • Karmanos Cancer Institute at McLaren FlintFlint, United StatesContact: Anthony F Shields, M.D.Taking people
  • University of Texas M.D. Anderson Cancer CenterHouston, United StatesContact: Kim RossTaking people
  • Karmanos Cancer Institute at McLaren Greater LansingLansing, United StatesContact: Anthony F Shields, M.D.Taking people
  • Karmanos Cancer Institute at McLaren Lapeer RegionLapeer, United StatesContact: Anthony F Shields, M.D.Taking people
  • Karmanos Cancer Institute at McLaren Central Michigan, Morey Cancer CenterMount Pleasant, United StatesContact: Anthony F Shields, M.D.Taking people

About the trial

What the trial wants to find out

The goal of this clinical trial is to learn if the TheraBionic P1 device given to patients with advanced hepatocellular carcinoma (HCC) who have no standard of care options can affect patients survival. The main questions it aims to answer are:

Read full original descriptionShow less

* will the TheraBionic P1 device affect overall survival in advance HCC * the long term safety and tolerability of the TheraBionic P1 device * assessment of how the disease responded to the TheraBionic P1 device

The group in the trial

  • TheraBionic P1 deviceTreatment being tested

    Self administered Amplitude-modulated electromagnetic fields three times daily

    Treatment: TheraBionic P1

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
TheraBionic P1 Device for Patients With Advanced Hepatocellular Carcinoma (HCC) Who Fail First and Second Line Therapy
Plain-language title
Tests a TheraBionic P1 device in adults with advanced liver cancerGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
12 November 2026